1.. Introduction {#s1}
================

The increase in life expectancy in human populations worldwide is a triumph of biomedical research. Survival rates started to increase in the mid-nineteenth century, because of improvements in public health, particularly clean water, immunization and antibiotics, and also because of other improvements in lifestyle such as better housing. The rate of increase in life expectancy in most countries does not yet show any sign of slowing and, indeed, is greatest in older age classes; we cannot yet see what any intrinsic limit to human life expectancy will be ([@RSTB20090222C96]; [@RSTB20090222C63]).

For a given age, health now is better than it was 150 years ago, but this welcome change is also producing great challenges. Many of these are socio-economic, concerning issues such as work force participation and affordability of pension schemes. Paradoxically, there is also a major medical problem. The improvement in individual health means that larger numbers of individuals reach older ages, and hence live long enough to suffer from ageing-related disease and loss of function. All of the major killer diseases, including cardiovascular disease, cancer and dementia, are strongly age related. The predominant burden of ill-health is now falling on the older section of the population and, both for health benefits to ageing individuals and economic benefits to the societies in which they live, we urgently need to discover means of improving health during ageing. Fortunately, major scientific opportunities have opened up in research into ageing and bring with them the enticing prospect of a broad-spectrum, preventative, medicine for diseases of ageing. However, taking the fruits of these scientific discoveries to the ageing human population may not be straightforward.

From the biological standpoint, the major features of ageing are an intrinsic decline in function during adulthood, leading to a drop in fecundity and increased likelihood of death ([@RSTB20090222C11]). Ageing is not inevitable and, indeed, some organisms seem not to age at all or to do so very slowly. Some even show an increase in fecundity or survival rate over at least part of adulthood. Ageing is particularly apparent in organisms where growth is completed before reproduction commences, such as insects, birds and many mammals, including humans ([@RSTB20090222C90]; [@RSTB20090222C1]). The major laboratory model organisms used for research into ageing, namely budding yeast *Saccharomyces cerevisiae*, the nematode worm *Caenorhabditis elegans*, the fruitfly *Drosophila melanogaster* and the mouse *Mus musculus*, all fall into this category and, in this sense at least, are good models for human ageing.

The phenotypes associated with ageing have been best studied in humans and are complex ([@RSTB20090222C48]). Within single tissues, multiple types of damage and pathology increase in incidence with age, and the spectrum of changes differs between tissues. The precise phenotypes of ageing are also notably variable between individuals ([@RSTB20090222C12]). This complexity and variability have led to a picture of the ageing process as intractable, for both experimental analysis and medical intervention. Indeed, it could be concluded that there is no single ageing process; rather, during ageing, a large number of independent and stochastic processes of damage accumulation occur in parallel, with little or no common causality. Amelioration of the impact of one type of ageing-related damage would, if this scenario is correct, leave the majority unaffected and would hence have little impact on overall ageing-related decline. This view of ageing permeates medicine to the present day. Geriatrics is largely a primary care medical speciality, with little input from basic and clinical research, unlike specific ageing-related diseases such as cancer, cardiovascular disease and neurodegeneration, which are all associated with sizeable and well-funded research communities. Specific diseases of ageing are generally viewed as medically tractable, unlike the ageing process itself.

The idea that ageing is difficult to modify has until recently been reinforced by work on its evolution. Evolutionary biologists have long been intrigued by ageing, because it is a deleterious trait, but it nonetheless shows great diversity in the natural world. After various ideas of a possible benefit of ageing to family groups or whole species were largely discredited ([@RSTB20090222C37]), the key insight came with the realization that, because of extrinsic causes of mortality such as disease, predation and accidents, the force of natural selection weakens for older age classes, because fewer individuals succeed in reaching them ([@RSTB20090222C17]; Medawar [@RSTB20090222C57], [@RSTB20090222C58]). A substantial body of theoretical analysis, experimentation and comparative work led to the conclusion that ageing can hence evolve as a side effect, either of pressure of new mutations that reduce fecundity or survival probability later in life or of mutations that have beneficial effects in the young ([@RSTB20090222C58]; [@RSTB20090222C95]; [@RSTB20090222C18]; [@RSTB20090222C23]; [@RSTB20090222C68]; [@RSTB20090222C60]). As far as we know, no genes have evolved to cause ageing. Unlike development, there is no well-oiled hierarchy of genetic regulation to ensure that ageing happens in the right tissues and at the right times. Instead, it is an unregulated side effect of the failure of natural selection to maintain function at the later ages that few individuals reach in nature ([@RSTB20090222C66]). These theoretical and practical insights have led to the conclusion that ageing is likely to be a highly polygenic trait, since many genes are involved in assurance of survival during adulthood and in promoting fecundity.

The complexity of the ageing phenotype and the realization that it is an evolutionary side effect, rather than an adaptive process, led to the widespread assumption that mutations in single genes were unlikely to be capable of slowing down ageing. Furthermore, it seemed improbable that mechanisms of ageing would be the same in different kinds of organisms. If different human tissues acquire such different forms of damage and pathology during ageing, presumably as a result of the different types of insults of daily living that they encounter then, by the same token, organisms with very different life styles would be expected to encounter different sources of damage ([@RSTB20090222C67]).

2.. Single-gene mutations that extend the lifespan of laboratory animals {#s2}
========================================================================

Perhaps the single most important advance in ageing research in recent years has been discovery of mutations in single genes that extend the lifespan of laboratory animals. They first came to light as a result of a systematic chemical mutagenesis screen for lifespan-extending mutations in *C. elegans* ([@RSTB20090222C39]). Subsequent work with these mutations ([@RSTB20090222C14]), and further screening ([@RSTB20090222C32]), revealed that it was possible to double the lifespan of the worm with a mutation in a single gene. Furthermore, rather than solely prolonging the moribund period at the end of the life, the mutations caused the worms to remain healthy and youthful for longer ([@RSTB20090222C32]). The mutated genes were discovered to encode components of an invertebrate insulin/insulin-like growth-factor-like signalling (IIS) pathway ([@RSTB20090222C35]; [@RSTB20090222C42]; [@RSTB20090222C64]). These findings came as a considerable surprise, because a signalling pathway previously associated with control of growth and metabolism in mammals now turned out to play a role in determination of lifespan in a distantly related invertebrate.

Mutations with similar effects on lifespan were soon discovered in other model organisms. For instance, a similar screening effort in yeast led to the discovery that over-expression of a protein deacetylase, *SIR2*, extended replicative lifespan ([@RSTB20090222C81]; [@RSTB20090222C28]), while mutations in *methuselah* in *Drosophila* increased fly lifespan ([@RSTB20090222C43]). Likewise, in the mouse, mutations in genes encoding transcription factors involved in the development of the pituitary gland resulted in long-lived dwarf mice ([@RSTB20090222C3]). By the late 1990s, it was firmly established that lifespan of these model organisms could indeed be extended by mutations in single genes.

It had also been known since the 1930s that an environmental intervention, dietary restriction (DR), could produce substantial increases in lifespan in laboratory rodents ([@RSTB20090222C53]). Although the exact mechanisms at work still await full elucidation, detailed study of DR rodents has demonstrated a broad-spectrum improvement in health and a delay in or amelioration of the impact of a wide range of ageing-related diseases (Masoro [@RSTB20090222C50], [@RSTB20090222C51]). For instance, the animals are protected against cancer, cataract, diabetes, motor decline, osteoporosis and nephropathy ([@RSTB20090222C92]). These findings suggested that, in principle, multiple aspects of the ageing phenotype could be simultaneously ameliorated by a single intervention, albeit, in the case of DR, a complex one.

3.. Evolutionary conservation {#s3}
=============================

The ultimate aim of biomedical research into ageing with animals is to improve the health of the older section of human populations. Laboratory model organisms have been key to understanding many other aspects of human biology. Embryonic development, the cell cycle, the functioning of the nervous system, cellular metabolism and many other processes have often been investigated by proceeding from simpler organisms to more complex ones. This process works because of evolutionary conservation of genes and their functions over the large evolutionary distances involved. Indeed, it is often possible to introduce a human gene into yeast or *Drosophila* and find that it functions quite normally there. However, because ageing is not an adaptive trait and because different kinds of organisms are exposed to different kinds of stress and damage, there has been a good reason to doubt that this kind of evolutionary conservation will apply to the ageing process.

DR extends lifespan not only in rodents but also in a wide range of distantly related organisms, including yeast ([@RSTB20090222C27]; [@RSTB20090222C44]), *C. elegans* ([@RSTB20090222C38]; [@RSTB20090222C41]; [@RSTB20090222C16]; [@RSTB20090222C31]; [@RSTB20090222C82]) and *Drosophila* ([@RSTB20090222C6]; [@RSTB20090222C5]). Indeed recent work has demonstrated that DR increases lifespan in rhesus monkeys ([@RSTB20090222C21]; [@RSTB20090222C52]; [@RSTB20090222C9]) and short-term DR can produce improvements in function in humans (e.g. [@RSTB20090222C21]). Because the details of the mechanisms by which DR extends lifespan are not fully elucidated for any organism, it is not clear whether this is a case of evolutionary conservation or whether instead there has been evolutionary convergence ([@RSTB20090222C45]).

It was originally suspected that extension of lifespan by reduced IIS might turn out to be a worm peculiarity. This was because mutations in genes in the IIS pathway can also cause the worms to enter a type of developmental arrest (dauer), normally seen only in response to low food or crowding ([@RSTB20090222C75]). Dauer larvae are long lived, and the long life of IIS mutant adult worms could therefore have been a result of re-expression in the adult of the genes that make the dauer larva long lived ([@RSTB20090222C32]), a speculation confirmed by studies of gene expression (McElwee *et al.* [@RSTB20090222C54], [@RSTB20090222C55]). Most organisms do not undergo this type of developmental arrest and might therefore lack the mechanisms for long life seen in dauer larvae. However, an important recent discovery has been that the IIS pathway has an evolutionarily conserved role in determining longevity; mechanisms of ageing therefore are, at least to some extent, 'public' or shared ([@RSTB20090222C67]). Remarkably, mutations in the single *Drosophila* insulin receptor ([@RSTB20090222C87]) and insulin receptor substrate ([@RSTB20090222C7]) proved to extend lifespan in the fly. Furthermore, mutations in the genes encoding both the insulin ([@RSTB20090222C2]) and Igf-1 receptor ([@RSTB20090222C22]) extended lifespan in the mouse. Subsequent work with all three organisms has amply confirmed the evolutionarily conserved role of this signalling pathway ([@RSTB20090222C78]; [@RSTB20090222C73]; [@RSTB20090222C86]). Early evidence from population--genetic association studies has also started to implicate the pathway in determination of human lifespan ([@RSTB20090222C59]; [@RSTB20090222C40]; [@RSTB20090222C94]).

Evidence for evolutionary conservation of genetic determinants of lifespan is at present strongest for the IIS pathway, but others are likely to lengthen the list. For instance, the effect of elevated expression of *SIR2* in yeast appears to be conserved in *C. elegans* ([@RSTB20090222C88]) and *Drosophila* ([@RSTB20090222C76]), and mutations in genes encoding components of the target of rapamycin (TOR) pathway also extend the lifespan in all four organisms ([@RSTB20090222C26]; [@RSTB20090222C30]; [@RSTB20090222C29]; [@RSTB20090222C19]; [@RSTB20090222C65]; [@RSTB20090222C80]; [@RSTB20090222C83]; [@RSTB20090222C20]). Sufficient single-gene mutations that extend lifespan in yeast and *C. elegans* have now been identified to allow a quantitative estimate of the degree of evolutionary conservation of genetic modifiers of ageing between these two organisms ([@RSTB20090222C83]). In *C. elegans*, loss of function of a set of approximately 276 genes, or altered function of their protein products, has proved to extend lifespan. A set of 103 yeast orthologues of 78 of these 276 worm genes could be identified on the basis of sequence similarity, and deletion of 76 of these resulted in viable yeast strains. Eleven of the 76 were long lived, a proportion 4.3 times higher than would be expected from deletion of the same number of randomly selected yeast genes. Many of the genes with a conserved role in ageing in these two organisms are involved in protein synthesis ([@RSTB20090222C83]), a process whose importance to ageing has recently been demonstrated by experimental studies in *C. elegans* ([@RSTB20090222C19]; [@RSTB20090222C65]). This strong signal of evolutionary conservation between these two distantly related organisms suggests that future studies of the role of protein synthesis in ageing in the fruitfly and the mouse would pay dividends.

Although there is abundant evidence for an evolutionarily conserved role for IIS and other pathways in determination of lifespan, it remains to be seen how deep that conservation penetrates. Even at the level of signalling mechanisms, there may be considerable variation between different organisms as is implied, for instance, by the presence of much larger numbers of insulin ligands in the worm (38) and the fly (7) than in mammals. In addition, similar changes in signalling in different organisms may have very different outcomes because of differences in structure and physiology. Of particular importance for IIS, insulin resistance and failure in insulin production can result in diabetes in mammals, with its consequent vascular damage, while the invertebrates, with their open circulatory systems, can probably better tolerate elevated blood sugar. Only a narrow range of alterations in IIS may therefore increase mammalian lifespan. There is some evidence for evolutionary conservation of the biochemical mechanisms by which altered IIS extends lifespan in different organisms. For instance, profiling of gene expression in long-lived, IIS mutant worms, flies and mice showed increased expression of genes encoding components of phase 1 and 2 detoxification pathway, important in the elimination of lipophilic endobiotics, xenobiotics and drugs ([@RSTB20090222C56]; [@RSTB20090222C85]; [@RSTB20090222C89]). Subsequent work with a key transcriptional regulator of the pathway has demonstrated experimentally that increasing its activity can increase lifespan in both *C. elegans* and *Drosophila* ([@RSTB20090222C56]; [@RSTB20090222C85]; [@RSTB20090222C89]). Cellular detoxification may therefore be an important process for protection against the effects of ageing in all three organisms, although whether the toxins involved are the same or different remains to be determined.

So far we have only scratched the surface of the mechanisms at work in lifespan extension. Nonetheless, these new findings have opened up the promise of a major scientific opportunity, to use the invertebrates and the mouse to understand human ageing, exploiting the full range of analytical tools available in the model organisms.

4.. Risk and damage {#s4}
===================

Slowing down ageing is not the only means by which lifespan can be extended. The ageing process is characterized by a decline in function with advancing age during adulthood; the state of the organisms progressively worsens. One might therefore expect that an intervention that extended lifespan by amelioration of the ageing process would do so by slowing down the rate at which state worsens with age ([@RSTB20090222C11]). A simple and direct way of assessing the state of a population is to measure mortality rate, which is, to a first approximation, the proportion of individuals that enter each age class that die during it. Mortality rates generally show a roughly exponential increase with age in humans and the laboratory model organisms and can hence be described in terms of two important parameters: the initial, baseline mortality rate, which is age independent, and the rate at which mortality rate increases with age ([@RSTB20090222C11]; [@RSTB20090222C74]). Interventions, genetic and environmental, that increase lifespan can do so by decreasing either or both of these parameters ([@RSTB20090222C74]). A reduction in the slope of a mortality trajectory is what would be expected if lifespan were increased by a reduction in the rate of ageing itself ([@RSTB20090222C11]).

One intervention that clearly can slow down the rate of ageing is lowered temperature for ectotherms. In *Drosophila*, lowered temperature increases lifespan entirely by lowering the slope of the mortality trajectory, with no effect on the initial mortality rate ([@RSTB20090222C46]). These flies are too small to thermoregulate and are thus forced to adopt ambient temperature. Lowering of the slope of the mortality trajectory in cooler environments is consistent with the idea that lowered temperature decreases the rate of most or all molecular processes in the organism, including the rate of ageing. In support of this view, when flies are switched between temperatures, the subsequent slope of the mortality trajectory immediately changes to that characteristic of flies kept permanently in the new thermal regime ([@RSTB20090222C46]). The flies therefore bear the permanent imprint of their thermal history, with warmer temperatures leading to the accumulation of a higher level of irreversible damage, and no acute effect of temperature on mortality rate. Lowered temperature thus decreases the rate of ageing in *Drosophila* and provides a useful benchmark for an intervention that does so.

Rather than decreasing the rate of ageing, the increase in lifespan in industrialized human societies has occurred by a reduction in baseline mortality rates, with no reduction in the slope of the mortality trajectory ([@RSTB20090222C96]). This suggests that overall health, at all ages, has improved, but that the underlying process of accumulation of ageing-related damage has not been ameliorated. This finding leaves open the question of the time course of these effects. For instance, events early in life or even *in utero* could have a lifelong impact on health, and there could also be more acute effects of recent and current environments. To measure such timing effects, it is necessary to compare individuals with currently similar circumstances but different past environments, and *vice versa*.

Interestingly, DR can have a similar effect on mortality trajectories to that associated with the increase in human lifespan expectancy; DR extends life in *Drosophila* entirely by reducing the initial mortality rate with no lowering of its slope ([@RSTB20090222C74]). Similar findings have been reported for DR in mice ([@RSTB20090222C93]; [@RSTB20090222C24]), and for one form of DR in *C. elegans* ([@RSTB20090222C82]), suggesting that, in these three organisms at least, DR may not slow down the rate of ageing and may instead increase lifespan through a different mechanism. Indeed, experimental reversal of the nutritional status of flies has shown that the effect of DR on mortality rate is acute. Later onset DR leads, within 48 h, to a switch in subsequent mortality rates to those of permanently DR flies ([@RSTB20090222C46]). Likewise, previously DR flies that are switched to full feeding at later ages show a rapid increase in mortality rates to those characteristic of flies that are permanently fully fed. DR and fully fed flies thus age at the same rate, and DR instead extends lifespan by reducing the acute risk of death.

There is little information on the timing of the effects of single-gene mutations on mortality rate. In *C. elegans*, switches in IIS status using double stranded RNA interference have shown that the pathway acts specifically during adulthood to determine adult survival ([@RSTB20090222C10]), but more detailed timing information is not yet available. In *Drosophila*, an inducible system for gene expression was used to show that, at least up to a month of adult age, the IIS pathway acts acutely to determine mortality rate, similar to DR ([@RSTB20090222C15]). It will be important to determine whether this kind of acute effect on mortality rate applies to other pathways that determine lifespan and, in particular, whether it extends to mammals. But it is already clear that, in principle, lifespan can be extended by making the animal less likely to die of the damage that it has accumulated, rather than by reducing the accumulation of damage.

5.. Ageing and ageing-related diseases {#s5}
======================================

It has long been known that DR in rodents reduces the impact of a wide range of ageing-related diseases, and it has also been shown to reduce the impact of proteotoxicity in *C. elegans* ([@RSTB20090222C84]). Because the single-gene mutations that extend lifespan have only been discovered recently, less information is available, but already it seems that aspects of function and health during ageing are improved. For instance, associative learning is more strongly maintained at later ages in long-lived IIS mutants worms ([@RSTB20090222C61]), while locomotor function is better maintained during ageing in long-lived IIS mutant flies ([@RSTB20090222C49]). Loss of the insulin receptor substrate 1 in the mouse also protects against loss of glucose homeostasis, immune and motor function and reduces the impact of osteoporosis, cataract and ulcerative dermatitis ([@RSTB20090222C79]). As well as maintaining function and health during ageing, lifespan-extending mutations can protect against the pathology associated with specific genetic models of ageing-related disease. For instance, recent work with *C. elegans* has revealed that mutations in IIS that increase lifespan can reduce the pathology associated with genetic models of cancer ([@RSTB20090222C71]; [@RSTB20090222C72]) and of proteotoxicity-induced neurodegeneration ([@RSTB20090222C8]; [@RSTB20090222C71]; [@RSTB20090222C84]). Furthermore, mutations in IIS in the mouse can protect against the pathology associated with specific genetic models of Alzheimer\'s disease ([@RSTB20090222C13]; [@RSTB20090222C34]). The indications are, therefore, that these interventions can produce an improvement in health and function in diverse tissue systems and reduce the impact of ageing-related diseases with diverse aetiology ([@RSTB20090222C4]).

The implication of these findings is that protection against the ageing process results in protection against diverse, ageing-related diseases. The ageing process itself is acting as the major risk factor for these conditions. This realization leads in turn to the conclusion that there is an underlying commonality in the aetiology of these ageing-related diseases, despite their diverse manifestations. It is early days yet, and a great deal more work needs to be done to understand exactly how the ageing process increases vulnerability to these diseases. We need also to understand how transition into loss of function and disease occurs, and how a single environmental intervention or gene mutation can have such broad-spectrum effects. A key challenge in the biology of ageing, and one that is increasingly being recognized, is to understand how events at different levels of organization contribute to loss of function during organismal ageing and to eventual death ([@RSTB20090222C36]; [@RSTB20090222C62]). Presumably, in a complex chain of events, damage to macromolecules and organelles causes decline in cellular function and cell loss, which in turn compromise the function of tissues. Dysfunctional tissues could in turn act systemically to cause stress and eventual damage to other tissues, which could to some extend cause a correlation in the rate of ageing of different parts of the body within an individual. Many of these key changes may be susceptible to acute intervention, similar to the effects of DR in the invertebrate model organisms. At some point, irreversibility must enter the system, because of the emergence of lethal, ageing-related disease that cannot be rescued by the intervention ([@RSTB20090222C70]). Identifying, experimentally investigating and modelling these temporal changes and their dynamics will require considerable effort, and in the near future much more experimental work will be needed to bring understanding of these systems to a level of maturity where productive modelling will be possible.

6.. Will lifespan extension in laboratory model organisms be relevant to human ageing? {#s6}
======================================================================================

The findings from the model organisms have a clear, potential message for the medical treatment of ageing-related diseases ([@RSTB20090222C4]). At present, these diseases are treated piecemeal by different medical specialists, because they are regarded as separate medical problems. Patients themselves generally visit a clinician because they have a specific medical problem, not because they are old. However, if in humans, also, protection against the effect of ageing can delay or ameliorate diverse ageing-related diseases, then a quite different approach to the health of older people would pay dividends. A broad-spectrum, preventative approach would be required, with individuals who reached a certain age being treated even in the absence of any ageing-related disease. Furthermore, if the effects of a beneficial intervention were acute, as has occurred in some of the animal models, then it would need to be applied for the rest of life. Clinical trials would also need to be conducted for a protracted period. All of these features would pose significant obstacles to translating the findings from basic science into drug development and clinical practice. However, if the findings from the animal models turn out to apply to humans, then a major opportunity could be missed. What, then, is the likelihood that evolutionary conservation of the mechanisms will extend to our own species?

There are some obvious questions about lifespan extension in animal models that have a bearing on likely relevance to humans. If these single gene mutations can produce such broad-spectrum benefits to health, then why is the mutant not the wild-type? These mutants must have side effects that mean that they are not the fittest genotype in the wild. Some mutants that extend lifespan clearly delay or reduce fecundity, as does DR ([@RSTB20090222C69]). However, it is also clear that, at least in the laboratory, impaired fecundity is not necessary for extension of lifespan by some single-gene mutations ([@RSTB20090222C69]), although some claims that this is the case may have been based on failing to measure all aspects of fecundity or doing so in benign circumstances ([@RSTB20090222C77]; [@RSTB20090222C91]; [@RSTB20090222C47]; [@RSTB20090222C25]). Nature is in general a more exacting place than the laboratory, where the animals are kept largely free of pathogens, have an abundant and highly accessible food supply and are kept largely free of competition with conspecifics. However, many of these considerations apply also to humans in developed countries. It will be important to evaluate what are the negative effects of single-gene mutations that make them disadvantageous under natural circumstances, to understand how important these might be for humans. It should also be borne in mind that medical interventions into ageing are likely to be applied only later in the lifespan, when some of the negative side effects may no longer be relevant, and it has already been demonstrated that administration of a TOR inhibitor, rapamycin, later in life in mice can extend the lifespan ([@RSTB20090222C20]). The prospects that the findings from the laboratory will prove to be of medical relevance to humans therefore look promising.

Humans are, obviously, much longer lived than any of the laboratory model organisms. This could have a bearing on the extent to which interventions could ameliorate the effects of ageing, or not. It is notable that many of the genes that have so far come to light as affecting longevity in the laboratory are involved in nutrient sensing pathways, which contribute to matching the growth and reproductive rate of the animals to their nutritional status. Human growth and reproduction respond to nutrients, but not to such an extent as do those of the laboratory model organisms, which are all subject to boom and bust conditions in nature. However, even if human lifespan is not as plastic as that of laboratory animals, the same may not be true for ageing-related disease. The aim of this research is to improve human health during ageing, not to extend lifespan *per se*, and it remains to be seen to what extent this is going to be possible.
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